Simulations Plus, Inc. (Nasdaq: SLP), a top provider of biosimulation, simulation-enabled performance, intelligence solutions, and medical communications for the biopharma industry, has announced an optimization of its business unit and…
bluebird bio, Inc. (Nasdaq: BLUE) announced on August 20, 2024, that it received notices from Nasdaq stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1). This is due…
Pfizer Inc. and BioNTech SE announced that the U.S. FDA has approved their supplemental Biologics License Application for the Omicron KP.2-adapted COVID-19 vaccine (COMIRNATY®) for individuals aged 12 and older.…
Verint® (NASDAQ: VRNT), known as The CX Automation Company™, has announced that a leading healthcare provider is significantly expanding its deployment of the Verint Interaction Wrap Up Bot, increasing its…
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Propofol Injectable Emulsion USP in single-dose…
QuantHealth, an AI-driven clinical trial design firm, has successfully simulated over 100 trials, achieving 85% accuracy and notable returns on investment for pharmaceutical partners. By utilizing its proprietary technology and…
Relief Mental Health, a top provider of transcranial magnetic stimulation (TMS), psychedelic therapy (including SPRAVATO® and IV ketamine), psychiatry, and talk therapy, has introduced TMS for smoking cessation at its…
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the FDA for Priority Review. This application, based on the positive ADRIATIC Phase III trial results in…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for…
Syros Pharmaceuticals (NASDAQ: SYRS) has announced it will halt enrollment in the SELECT-AML-1 Phase 2 trial, which is assessing the triplet combination of tamibarotene, venetoclax, and azacitidine versus the doublet…
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) has announced its financial results for the second quarter and six months ending June 30, 2024, along with a corporate update. CEO Michael…
Prothena Corporation plc (NASDAQ:PRTA), a leader in protein dysregulation-based therapies, reported its financial results for Q2 and the first half of 2024, alongside key business updates. Second Quarter and 2024…